Clinical Trials Sponsored by Eli+Lilly+and+Company

Total 2623 results

Eli Lilly and Company

Completed

A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer

Superficial Bladder Cancer

Israel
Eli Lilly and Company

Completed

Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis

Osteoporosis, Postmenopausal

Canada, United States
Eli Lilly and Company

Completed

Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

Non-Small-Cell Lung Carcinoma

United States
Eli Lilly and Company

Completed

Effects of Arzoxifene on Bone Mass and the Uterus

Postmenopausal Bone Loss

United States
Eli Lilly and Company

Completed

Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/Adolescents

Attention Deficit Hyperactivity Disorder

United Kingdom
Eli Lilly and Company

Completed

A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric Carcinoma

Advanced Gastric Carcinoma

Italy
Eli Lilly and Company

Completed

A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma

Mesothelioma

Canada
Eli Lilly and Company

Completed

A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung

China, Taiwan, Australia, Korea, Republic of, Egypt, Romania, India, Turkey
Eli Lilly and Company

Completed

Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma

Mesothelioma

United States
Eli Lilly and Company

Completed

Biomechanical and Electrophysiological Effects of Duloxetine in the Treatment of Women With Urinary Stress Incontinence

Urinary Stress Incontinence

United States, Slovenia, United Kingdom
Eli Lilly and Company

Completed

Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer

Carcinoma, Non Small Cell Lung

United States
Eli Lilly and Company

Completed

Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer

Breast Cancer | Neoplasm Metastasis

Russian Federation
Eli Lilly and Company

Completed

Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder

United States
Eli Lilly and Company

Completed

Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Lung Neoplasms

United States
Eli Lilly and Company

Completed

Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder

Bipolar Disorder

United States, Lithuania, Puerto Rico, Romania, Russian Federation
Eli Lilly and Company

Completed

Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.

Non-Small-Cell Lung Carcinoma

Argentina, Brazil, Chile, Mexico
Eli Lilly and Company

Completed

A Comparison of Tolerability and Efficacy of Different Doses of Duloxetine for the Treatment of Major Depressive Disorder

Depressive Disorder

United States
Eli Lilly and Company

Completed

A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)

Sepsis

Germany
Eli Lilly and Company

Completed

The Effect of Growth Hormone in Very Young Girls With Turner Syndrome

Turner Syndrome

United States
Eli Lilly and Company

Completed

Duloxetine in the Treatment of Melancholic Depression

Depressive Disorder, Major

Australia, Canada
Eli Lilly and Company

Completed

Switching to Duloxetine From Other Antidepressants

Major Depressive Disorder

Spain, France, Ireland, United Kingdom
Eli Lilly and Company

Completed

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression

Major Depressive Disorder

United States, Canada
Eli Lilly and Company

Completed

A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

Schizophrenia

United States
Eli Lilly and Company

Completed

A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

Carcinoma, Non-Small-Cell Lung | Neoplasms, Lung | Pulmonary Neoplasms

United States
Eli Lilly and Company

Completed

ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.

Carcinoma, Non-Small-Cell Lung

United States
Eli Lilly and Company

Completed

EVA: Evista Alendronate Comparison

Osteoporosis

United States, Canada
Eli Lilly and Company

Completed

A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium

Urologic Neoplasms | Metastases, Neoplasm

United States
Eli Lilly and Company

Completed

A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, France, Germany, Taiwan, Spain, Belgium, Switzerland, Netherlands, Russian Federation, South Africa, Poland, Hungary, Italy, Norway, India, Sweden, Argentina, United Kingdom, Puerto Rico, Chile, Romania
Eli Lilly and Company

Completed

Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

Schizophrenia

United States, United Kingdom, Spain, Argentina, Mexico, Brazil, Peru, Puerto Rico, Germany, Austria, Ireland, Venezuela
MedSIR
Eli Lilly and Company

Active, not recruiting

ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL (ABIGAIL)

Breast Cancer Metastatic

Italy, Spain, Portugal
MacroGenics
Eli Lilly and Company

Terminated

Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States, Israel, United Kingdom, Poland, France, Germany, Belgium, Finland, India, Ukraine, Spain, Czechia, Italy, Mexico, Netherlands, Romania
MacroGenics
Eli Lilly and Company

Completed

The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States, Spain, Israel, Canada, India, Czechia, Ukraine, Sweden, Latvia, Mexico, Germany, Poland, Romania, Estonia, Netherlands, United Kingdom
Pfizer
Eli Lilly and Company

Completed

Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies

Osteoarthritis | Cancer Pain | Recurrent Low Back Pain

United States
Eli Lilly and Company
Celgene

Completed

A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

Carcinoma, Non-Small Cell Lung Cancer (NSCLC)

United States
AstraZeneca
Eli Lilly and Company

Terminated

A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

Alzheimer's Disease

United States, Spain, Australia, Belgium, Korea, Republic of, United Kingdom, Germany, Poland, Canada, Japan, Romania, France, Puerto Rico, Hungary
AstraZeneca
Eli Lilly and Company

Completed

A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

Healthy

United States
AstraZeneca
Eli Lilly and Company

Completed

A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin

Healthy

United States
Eli Lilly and Company
Shionogi

Completed

An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480)

Osteoarthritis of the Knee

Japan
Eli Lilly and Company
AstraZeneca

Completed

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

Spain, United States, Korea, Republic of, France, Italy
Eli Lilly and Company
AstraZeneca

Withdrawn

A Study of LY3314814 in Participants With Liver Impairment

Hepatic Impairment

United States
Eli Lilly and Company
Shionogi

Completed

An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain

Back Pain Lower Back Chronic

Japan
AstraZeneca
Eli Lilly and Company

Completed

A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
AstraZeneca
Eli Lilly and Company

Completed

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

Type 2 Diabetes Mellitus

United States, Czech Republic, France, Korea, Republic of, Russian Federation, Spain, Mexico, Australia, Belgium, Denmark, Germany, Hungary, Netherlands, Puerto Rico, Greece, Taiwan
AstraZeneca
Eli Lilly and Company

Completed

CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy

Type 2 Diabetes Mellitus

Sweden, Germany, Greece, Denmark, France
AstraZeneca
Eli Lilly and Company

Completed

A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects

Type 2 Diabetes Mellitus

Korea, Republic of, China, Japan, Taiwan, India
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Australia, France, Italy, Korea, Republic of, Mexico, Spain, Poland, Romania, South Africa, Argentina, Austria, Belgium, Germany, Hungary, Israel, Slovakia, Greece, India, Taiwan, Canada, Czech Republic
AstraZeneca
Eli Lilly and Company

Completed

A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Sweden, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Estonia, Romania, Finland, Netherlands, Argentina, Belgium, Germany, Portugal, United Kingdom, Greece, France, Puerto Rico
AstraZeneca
Eli Lilly and Company

Completed

Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Germany
AstraZeneca
Eli Lilly and Company

Completed

Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Ireland, United Kingdom
AstraZeneca
Eli Lilly and Company

Completed

Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Finland, Netherlands, Sweden

Clinical Trials Sponsored by Eli+Lilly+and+Company

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations